Enhanced productivity and functionality of Modified Ribosomally Produced Peptides (M-RIPPs)

核糖体产生的肽（RIPPs）被广泛认为是最有前途的一类化合物，具有治疗多种疾病的潜力，包括感染，癌症和炎症。它们对制药行业非常感兴趣，但生产/修改成本极高-即使是毫克量。通过利用组合合成生物学的尖端技术，该项目旨在实现世界第一;即，在体内生产定制的修饰RIPPs（M-RIPPs）文库，并以足够的数量允许药物发现筛选。该项目结合了两个主要的英国学术团体在该领域的RIPP生物合成所涉及的自然过程的基本知识，以及英国领先的IB公司在工业生物合成方面的应用专业知识。它将为体内M-RIPPs的生产提供一个多功能且强大的技术平台，该平台将在项目开始后约18个月转移到一家分拆公司。

Ribosomally Produced Peptides (RIPPs) are widely recognised as one of the most promising classes of compounds with the potential to treat many diseases including infection, cancer & inflammation. They are of great interest to the pharma industry, but are extremely costly to produce/modify - even in milligram amounts. Through the utilisation of cutting-edge techniques in combinatorial synthetic biology, this project sets out to achieve a world first; namely, to produce bespoke libraries of Modified RIPPs (M-RIPPs) in vivo and in sufficient quantities to permit drug discovery screening. The project combines the fundamental knowledge of the natural processes involved in RIPP biosynthesis of the two premier UK academic groups active in the field with the applied expertise in industrial biosynthesis of a leading UK IB company. It will deliver a versatile yet robust technology platform for the production of M-RIPPs in vivo that will be transferred to a spinoff company to be formed around 18 months after project start.